In recent years, there has been considerable interest in DDAH1 as a potential target for indirect inhibition of NO synthesis in diseases that produce excessive amounts of NO, such as septic shock,10 and aberrant neovascularization,11 including cancers such as melanoma,12 prostate cancer,13 and breast cancer.11 The gene discussed is DDAH1; the disease is prostate carcinoma.